reMYND
Gaston Geenslaan 1
3001 Leuven
BE
reMYND
Foundation date
07/02/2002
Sector
#Biotechnology - TherapeuticsSubsector
- #Therapeutics - Small molecules
- #R&D Services - CRO (Contract Research Organization)
- #R&D Services - Screening
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the nervous system
- #Endocrine - nutritional and metabolic diseases
reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).
Upcoming events
All events-
1605 '24
Knowledge for Growth 2024
Event by: flanders.bio -
1505 '24
State of the Union by VIB & flanders.bio
Event by: flanders.bio & VIB -
2105 '24
IOT Solutions World Congress 2024
Event by: Fira Barcelona
Latest news
More news-
V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors
1 day ago
Read more
-
Labconsort and NEKTARI join forces for a more sustainable and social industry
Saturday April 20th 2024
Read more
-
BIO INX Complements Advisory Board with Distinguished Industry Leaders
Thursday April 18th 2024
Read more
Jobs
More jobs-
24/04/24
Brussels
Laboratory Technician / Scientific Collaborator in Protein Biochemistry
Permanent
VIB -
23/04/24
Brussels
PhD Student Position: Fluorescent Biosensors in Neurodegenerative Diseases
Permanent
VIB -
23/04/24
Flemish Brabant
PhD Research position: multi-omics liquid biopsy platform to advance precision cancer medicine. (ref. BAP-2024-251)
Temporary
KU Leuven
More info?
Ellen Telleir
Communication Coordinator